The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II study of vismodegib in patients with SMO or PTCH1 mutated tumors: Results from NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol T.
 
Anne S. Tsao
Consulting or Advisory Role - ARIAD; AstraZeneca/MedImmune; Boehringer Ingelheim; Bristol-Myers Squibb; EMD Serono; Epizyme; Genentech/Roche; HERON; Lilly; Novartis; Takeda
Research Funding - Boehringer Ingelheim; Bristol-Myers Squibb; Bristol-Myers Squibb; EMD Serono; Genentech/Roche; Merck; Millennium; Polaris; Seagen; Seagen; Takeda
Patents, Royalties, Other Intellectual Property - UptoDate
 
Zihe Song
No Relationships to Disclose
 
Alan Loh Ho
Consulting or Advisory Role - AffyImmune Therapeutics; AstraZeneca; Ayala Pharmaceuticals; Bristol-Myers Squibb; Cellestia Biotech; CureVac; CureVac; Eisai; Eisai; Exelixis; Genzyme; InxMed; Kura Oncology; McGivney Global Advisors; Merck; Novartis; Prelude Therapeutics; Regeneron; Rgenta; Sanofi; Sun Pharma; TRM Oncology
Speakers' Bureau - Medscape; Novartis; Omniprex America
Research Funding - Allos Therapeutics; Astellas Pharma; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Ayala Pharmaceuticals; Ayala Pharmaceuticals; Bayer; Bayer; Bayer; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Daiichi Sankyo; Eisai; Elevar Therapeutics; Genentech/Roche; Kolltan Pharmaceuticals; Kura Oncology; Lilly; Merck; Novartis; Novartis; Novartis; Novartis; Pfizer
Travel, Accommodations, Expenses - Ayala Pharmaceuticals; Ignyta; Janssen Oncology; Klus Pharma; Kura Oncology; Kura Oncology; Kura Oncology; Merck
 
Janice M. Mehnert
Stock and Other Ownership Interests - Pfizer
Honoraria - EMD Serono; Pfizer/EMD Serono
Consulting or Advisory Role - Bristol-Myers Squibb; Eisai; Merck Sharp & Dohme; Novartis; Sanofi/Regeneron; Sanofi/Regeneron; Seagen
Research Funding - Amgen (Inst); AstraZeneca (Inst); bristol myers squibb (Inst); Incyte (Inst); macrogenics (Inst); macrogenics (Inst); Merck (Inst); Novartis (Inst); Regeneron (Inst)
Travel, Accommodations, Expenses - Array BioPharma; Bristol-Myers Squibb; EMD Serono; Merck Sharp & Dohme
 
Edith P. Mitchell
Leadership - Corvus Pharmaceuticals
Honoraria - Exelixis; Sanofi
Consulting or Advisory Role - Bristol Myers Squib; Genentech; Merck; Novartis
Speakers' Bureau - Ipsen
Research Funding - Genentech (Inst); sanofi (Inst)
 
John Joseph Wright
No Relationships to Disclose
 
Naoko Takebe
No Relationships to Disclose
 
Robert James Gray
Research Funding - Abbvie; Agios; Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Genentech/Roche; Genomic Health; Genzyme; GlaxoSmithKline; Janssen-Ortho; Merck Sharp & Dohme; Novartis; Onyx; Pfizer; Sanofi; Sequenta; Syndax; Takeda
 
Victoria Wang
No Relationships to Disclose
 
Lisa McShane
No Relationships to Disclose
 
Larry V. Rubinstein
No Relationships to Disclose
 
David R. Patton
No Relationships to Disclose
 
P. Mickey Williams
No Relationships to Disclose
 
Stanley R. Hamilton
Research Funding - Intima; Minerva Biotechnologies
 
Barbara A. Conley
No Relationships to Disclose
 
Carlos L. Arteaga
Stock and Other Ownership Interests - Provista Diagnostics
Consulting or Advisory Role - Arvinas; AstraZeneca; Athenex; Daiichi Sankyo; Immunomedics; Lilly; Merck; Novartis; Origimed; Puma Biotechnology; Radius Health; Sanofi; Taiho Pharmaceutical
Research Funding - Lilly; Pfizer; Takeda
Other Relationship - Susan G. Komen for the Cure
(OPTIONAL) Uncompensated Relationships - Susan G. Komen for the Cure
 
Lyndsay Harris
Patents, Royalties, Other Intellectual Property - Philips Healthcare
 
Peter J. O'Dwyer
Consulting or Advisory Role - Genentech
Research Funding - Amgen (Inst); Array BioPharma (Inst); BBI Healthcare (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Five Prime Therapeutics (Inst); Forty Seven (Inst); Genentech (Inst); GlaxoSmithKline (Inst); H3 Biomedicine (Inst); Lilly/ImClone (Inst); Minneamrita Therapeutics (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Pharmacyclics (Inst); Syndax (Inst); syndax (Inst); Syndax (Inst); Syndax (Inst); Syndax (Inst); Taiho Pharmaceutical (Inst)
Expert Testimony - Dai-ichi Sankyo; Lilly
 
Alice P. Chen
(OPTIONAL) Uncompensated Relationships - Frontiers in Medicine
 
Keith Flaherty
Stock and Other Ownership Interests - ALX Oncology; Apricity Health; Checkmate Pharmaceuticals; Clovis Oncology; FOGPharma; Kinnate Biopharma; Loxo; Monopteros Therapeutics; Nextech Invest; Oncoceutics; PIC Therapeutics; Scorpion Therapeutics; Soley Therapeutics; Strata Oncology; Transcode Therapeutics; Tvardi Therapeutics; Vibliome Therapeutics; X4 Pharma; xCures
Consulting or Advisory Role - Debiopharm Group; Lilly; Novartis; Oncoceutics; Takeda; Tvardi Therapeutics